Senesco Technologies Receives Notice of Non-Compliance from NYSE MKT

Senesco Technologies Receives Notice of Non-Compliance from NYSE MKT

Senesco Technologies, Inc.Leslie J. Browne, Ph.D., 908-864-4444President & CEO

On August 22, 2012, Senesco Technologies, Inc. (NYSE MKT: SNT) received a notice from NYSE Regulation, Inc. on behalf of NYSE MKT LLC providing notification that NYSE MKT has determined not to grant the Company an extension to the Company's time period to cure the Company's non-compliance with certain of the NYSE MKT's continued listing standards as set forth in Part 10 of the NYSE MKT Company Guide, and therefore, the NYSE MKT intends to file a delisting application with the Securities and Exchange Commission striking the Company's common stock from the NYSE MKT. Specifically, the Company is not in compliance with Section 1003(a)(iii) of the Company Guide with stockholder's equity of less than $6,000,000 at June 30, 2011 and losses from continuing operations and/or net losses in its five most recent fiscal years and with Section 1003(a)(ii) of the Company Guide with stockholder's equity of less than $4,000,000 at September 30, 2011 and losses from continuing operations and/or net losses in three of its four most recent fiscal years. The Company reported stockholder's equity of $4,517,463 at June 30, 2011 and 3,933,130 at September 30, 2011.

The Company intends to appeal the NYSE MKT's determination and request a hearing a committee of NYSE MKT in accordance with the Company's rights as set forth in Sections 1203 and 1009(d) of the Company Guide. There can be no assurance that the Company's request for continued listing will be granted. If the Company's appeal is not successful, the NYSE MKT will likely initiate delisting proceedings.

Senesco, a leader in eIF5A technology, is running a clinical study in multiple myeloma with its lead therapeutic candidate SNS01-T, which targets B-cell cancers by selectively inducing apoptosis by modulating eukaryotic, translation, initiation Factor 5A (eIF5A), which is believed to be an important regulator of cell growth and cell death. Accelerating apoptosis may have applications in treating cancer, while delaying apoptosis may have applications in treating certain inflammatory and ischemic diseases. Senesco has already partnered with leading-edge companies engaged in agricultural biotechnology and biofuels development, and is entitled to earn research and development milestones and royalties if its gene-regulating platform technology is incorporated into its partners' products.

Suggested Articles

How long can one infusion of CAR-T drug Yescarta continue helping patients with refractory large B-cell lymphoma? Pretty long, Gilead showed Saturday.

AbbVie and Roche have fielded their fair share of questions about how well their fixed-duration regimen of Venclexta and Rituxan can keep CLL at bay.

Saturday, AstraZeneca revealed more of the data that convinced the FDA to green-light Calquence in previously untreated chronic lymphocytic leukemia.